Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
NRXPW NRX PHARMACEUTICALS INC C/WTS 24/05/2026 (TO PUR COM)
0.3500.0000.00%
Close
01/31 16:00 ET
High
0.000
Open
0.350
Turnover
6.00
Low
0.000
Pre Close
0.350
Volume
18.00
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
NRx Pharmaceuticals GAAP EPS of -$0.14
NRXP FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages NRx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important March 21 Deadline in Securities Class Action - NRXP, NRXPW
Newsfile 15-Mar-2022 12:35 PMNew York, New York--(Newsfile Corp. - March 15, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NRx Pharmaceutical
FCFS, VWAGY & NRXP Deadline Alerts: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Deadlines
ACCESSWIRE 11-Mar-2022 11:01 AMNEW YORK, NY / ACCESSWIRE / March 11, 2022 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following p
ROSEN, A TOP RANKED LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPW
Newsfile 10-Mar-2022 6:10 PMNew York, New York--(Newsfile Corp. - March 10, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NRx Pharmaceuticals
NRX INVESTOR NEWS: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSE, Encourages NRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - NRXP, NRXPW
Newsfile 7-Mar-2022 4:45 PMNew York, New York--(Newsfile Corp. - March 7, 2022) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of NRx Pharmaceuticals,
NASDAQ TRADE HALT NRXPW.O HALT NEWS PENDING AT 06:01 PM
NASDAQ TRADE HALT NRXPW.O HALT NEWS PENDING AT 06:01 PM
No More
Company Overview
More
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
CEO： Mr. Stephen H. Willard
Market： NASDAQ
Listing Date： 12/01/2017
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet